Leaders in Pharmaceutical Business Intelligence (LPBI) Group

2016 Strategic Plan for LPBI Group – DRAFT

 

UPDATED ON 2/16/2016

We are developing Technologies we will be presenting for funding in CLUSTERS of Solutions for three Drug Indications:

 

• Diabetes

http://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/subsidiary-5-joint-ventures-for-ip-development-jvip/drug-discovery-with-3d-bioprinting/diabetes-a-combination-drug-therapy-to-induce-insulin-production-by-pancreatic-beta-cells-ppar-gamma-leptin/

 

• Inflammatory Disorders– with or without Cancer Impact

Autoimmune Inflammtory Bowel Diseases: Crohn’s Disease & Ulcerative Colitis – Potential Roles for Modulation of Interleukins 17 and 23 Signaling for Therapeutics

Curators: Larry H Bernstein, MD FCAP and Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2016/01/23/autoimmune-inflammtory-bowl-diseases-crohns-disease-ulcerative-colitis-potential-roles-for-modulation-of-interleukins-17-and-23-signaling-for-therapeutics/

Cytokines in IBD

Curators: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2016/02/13/cytokines-in-ibd/

Collagen-binding Molecular Chaperone HSP47: Role in Intestinal Fibrosis – colonic epithelial cells and subepithelial myofibroblasts

Curators: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2016/01/25/collagen-binding-molecular-chaperone-hsp47-role-in-intestinal-fibrosis-colonic-epithelial-cells-and-subepithelial-myofibroblasts/

IBD: Immunomodulatory Effect of Retinoic Acid – IL-23/IL-17A axis correlates with the Nitric Oxide Pathway

Curators: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2016/01/25/ibd-immunomodulatory-effect-of-retinoic-acid-il-23il-17a-axis-correlates-with-the-nitric-oxide-pathway/

Intestinal Inflammatory Pharmaceutics

Curator: Larry H. Bernstein, MD, FCAP

http://pharmaceuticalintelligence.com/2016/02/11/intestinal-inflammatory-pharmaceutics/

How could we develop such capabilities — what type of relations should we explore with the Cambridge, MA company

Intestinal Inflammatory and Pharmaceutics

http://pharmaceuticalintelligence.com/2016/02/11/intestinal-inflammatory-pharmaceutics/

and

http://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/subsidiary-5-joint-ventures-for-ip-development-jvip/drug-discovery-with-3d-bioprinting/ibd-inflammatory-bowl-diseases-crohns-and-ulcerative-colitis/

 

• Anti-Cancer – CAR–T and TCRL

http://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/subsidiary-5-joint-ventures-for-ip-development-jvip/drug-discovery-with-3d-bioprinting/anti-cancer-car-t/

AND

LPBI Group’s PREFERRED decision for Drug Discovery / Therapeutics Design and Drug Delivery, involves:

• Drug-Devices vs Stand alone Active Agents
• Combination Drug therapies vs. Single Agents
• JOINT solutions of Drug-Devices and Combination Drug therapy as maintenance
• Drug Delivery System: Smart Polymers 

 

FUNDING INVOLVEMENT of GDE Enterprises with Third Parties IP Owners, would involve the following universe of entities: 

• Biologics Inventor X’s IP available for licensing via Yissum
• Yissum’s current Portfolio

http://www.yissum.co.il/technologies/life-science-and-biotechnology/44727

• Yissum’s IP Licensed to Yossi’s Commercialization Start up
• Technion’s Technology Transfer Office – T–cube Invent@Technion

http://t3.trdf.co.il/overview

• Weitzman Institute’s Technology Transfer Office – YEDA

http://www.yedarnd.com/

 

LPBI Group had in 2016 an Internal R&D efforts in Drug Discovery and we present to investors Opportunities for Funding in the following INDICATION areas:

1. Diabetes,
2. Inflammatory
3. Anti-Cancer.

R&D efforts in Drug Discovery are being planned in collaboration with Dr. Raphael Nir, CEO, SBH Sciences, Inc.

In 3Q 2015 Dr. Nir has proposed to GDE the concept of a Joint Venture.

Dr. Nir’s resources include the following:

• EBITA of his US based, SBH Sciences, Inc. profitable Biotech Co.
• Lab capabilities for the Team to use, I.e., Rent on demand in his incubator
• Nir joined our very creative interdisciplinary Team in R&D
• Nir’s expertise in Pre-Clinical R&D management, cell and molecular Biology
• Nir’s expertise in cytokines (Inflammatory) and gelatin three (Cancer)

LPBI Group’s resources include the following resources:

• The R&D Team
• Investment infrastructure of Global contacts in the Investment Community for Biotech Ventures
• R&D leadership and Team building by Aviva Lev-Ari, PhD, RN

All the Biologics we are adding NOW to our portfolio for funding are FOCUSED in 1,2,3, above. Exception:

• We represent Dr. Shamir’s OBGYN Biologics in a Two Drug-Device Solution to our Investment Placement Agency in NYC

The Process of Representation of a Third Party for purposes of Funding involve the following steps:

1. The Third Party needs to identify Drug Discovery funding Target opportunities that belong to INDICATIONS 1,2,3, listed, above
2. These opportunities identified in A, above, need to be presented to the Team by the Inventor over Skype per our PROCESS of decision making of inclusion for representation to our Investors.

We defined a process of ELEVEN steps. Our first cycle starts with Dr. Yedgar on 3/7/2016. He presented to the Team in November 2015, first time. This is his second presentation to the Team.

 

Eleven STEPS in the WORKFLOW FOR FUNDING INVOLVEMENT of LPBI Group with Third Parties IP Owners

CASE STUDY: Explorations for funding with Biologics Inventor X

1. Aviva and Biologics Inventor X will meet on ______at 9AM EST, location TBA, optimal at Aviva’s place
2. LPBI Group’s EAW(s) will arrive to to meet Biologics Inventor X
3. We will be on Skype for Biologics Inventor X Presentation to the Team from 9AM EST to 10:30AM EST: Mechanism of Action and all US Patents with time stamp to expiration– Team will receive by e-mail the Presentation in attachment prior to Presentation
4. Team’s discussion of the Presentation 10:30AM EST to 11:30AM EST
5. Team’s session adjourn at 11:30AM EST
6. Biologics Inventor X, EAW(s) and Aviva will continue talking on the Commercialization potential and “How to go about that”

Vegetarian Lunch

EAW(s) and Biologics Inventor X, Adjourn at 1:30PM EST

Biologics Inventor X and Aviva, adjourn at 2PM EST

 

Our Team activities related to 1 to 6, above – To FOLLOW:

7.   On ____9AM EST —EAW(s), Gerard and Aviva will discuss our joint strategy on Skype regarding DRUG DISCOVERY on one or more of the following:

Diabetes

• Inflammatory Disorders
• Anti-Cancer

as one candidate in the Pipeline of the Joint Venture [may comprise a proposal for three NCE], the other two in the Joint Venture pipeline are Diabetes [Stem cells and Combination drug therapy in Drug-Device] and Anti-Cancer [CAR-T and TCRL]

We will be preparing the

• Drug Discovery Plan,
• Drug Delivery Plan

for the Joint Venture LPBI Group’s Investment Partners.

8.  On ____ Team meeting at 10AM EST: Team will discuss of the Strategy presented by Gerard and Aviva, per discussions with Biologics Inventor X, third component by EAW(s) may be added

Team, please add the____, 9AM to 11:30AM to your Calendar. Please e-mail if you must be absent, otherwise, please attend and participate in the discussion following the Presentation

9.  Any additional parties, including Joint Venture Partners, please add the ____, 9AM to 1:30PM to your Calendar, visit to Aviva and in person meeting with Biologics Inventor X. Please Confirm your attendance by reply to ALL

Joint Venture Partners, please add ______9AM EST (Strategy discussion with Aviva and Gerard on Skype) and _______10AM EST (Team discussion of Strategy on Skype)

10.   Third Party IP representative will present to LPBI Group Team, Drug Discoveries Candidates, and the Inventors, that the Representative wishes to present to our Team
11.  We will decide on inclusion.

For example:

 

D.1   On Diabetes

D.1.1 ours

D.1.2 third party

 

D.2 On Inflammatory Disorders

D.2.1 ours

D.2.2 third party: Yedgar, Yossi and others

 

D.3  On Anti-Cancer: we will present to investors

D.3.1 our effort and

D.3.2 the opportunities at Woodland Pharmaceutical and X,Y,Z by third party, inventor and discovery

 

We @LPBI Group believe that, THAT type of presentation to Investors demonstrate to them the following Business advantages:

1.     LPBI Group is an R&D outfit representing a Joint Venture with SBH Sciences, Inc. a US based profitable Biotech with $10Million in Sales that has reached out to LPBI Group for its TEAM of MDs and PhDs to JOINTLY DEVELOP a pipeline of NCE.
2.     LPBI Group is being approached by Third Parties for Funding in 1,2,3 Drug Indications
3.     LPBI Group has an Eleven Steps Process for SCREENING drug candidates in which the TEAM and Dr. Nir are involved in decision making on what New Chemical Entities (NCE) to present to Investors, thus, shortening the Due Diligence to be done by the investors
4.     The Investors are given CHOICES to channel each DRUG DISCOVERY Project to a direct investor selected by them per “portfolio fit” and past interactions with given Drug Indications and Drug Classes we represent.

1,2,3,4 – will guarantee that our contacts in the Investment Community: NYC, Paris, Europe, Shanghai — will perceive GDE as a WHOLESALE channel with a robust pipeline of Drug Discovery Projects at hand.

Funding will be awarded to:

Type One:

3rd Party IP, i.e., Yossi/Yissum, Yedgar/Yissum, YEDA (Weitzman), T-cube (Technion)

• We will be on FINDER FEE AGREEMENTS with each party, same terms and conditions

Type Two:

Investments in the Joint Venture: LPBI Group + SBH Sciences, Inc.

• Investors assuming an Equity position

 

UPDATED ON 2/2/2016

 

Gerard’s Voice on GDE Enterprises Strategy February 2, 2016

Author: Gerard LOISEAU, ESQ

http://pharmaceuticalintelligence.com/2016/02/02/gerards-voice-on-gde-enterprises-strategy-february-2-2016/

 

UPDATED on 1/10/2016

 

UPDATED 2016 Strategic Plan for GDE Enterprises

In 2016 we are involved in business development and in Intellectual Property Creation by the M3DP Team

Subsidiary #1: LPBI

• Journal 

PLAN: Add new EAWs, reach 1.8Million e-Readers 12/2016.

• BioMed e-Series

PLAN: Publish SEVEN e-Books on Amazon.com:

CVD 5,6; Series E: Volumes 1,2,4; Series C: Cancer, Volume 2; Series B: Genomics, Volume 2 –Call it MISSION ACCOMPLISHED 12/2016.

• Biotech Conferences

PLAN: cover 2-6 conferences

Approved: 4/2016 Partners HC– International Cancer

Pending Approvals: 4 conferences by CHI

Subsidiary #2: Funding Early Stage Biologics Drug Development and Medical Device Development 

• Dr. Shamir – three ventures [$10Mil, $10Mil, $12Mil]
• ValveCure – M&A
• New Medicine — M&A
• Yossi —>> Yissum Five Drugs

Subsidiary #3: Medical 3D BioPrinting, TEAM involved in Product Concepts Development using

• BioMEMS for Gene Editing
• BioMEMS for Tissue Engineering
• BioMEMS and Stem Cells for Gene Therapy and Regenerative Medicine.

Subsidiary #4: US  Patents

• Dr. Pearlman
• Bill Zurn
• Dr. Yedgar
• Yossi’s Portfolio

Subsidiary #5 JOINT VENTURES —>>>>> We plan to present to Cukierman & Co. for funding, GDE’s engagement in Drug Discovery  

New Strategic Directions for GDE Enterprises: Joint Ventures in Drug Discovery

1.  Joint Venture of GDE with SBH Sciences, Inc (Dr. Nir, CEO) for Drug Discovery of a Novel Drug-Device for Diabetes, 

– new Combination Drug Therapy by my own Team,

– new Drug-Device Design by my own Team,

SBH brings to the Table

(a) a Positive Balance sheet

(b) an Accelerator/Incubator Lab facility in Natick, MA

(c) the Proposal for the Joint Venture

2. For Inflammatory Bowel Disease– Collaboration with Alma Bio, Lyon, France, potential Joint Venture (Dr. Nir Chairman and Investor)
3. Bio markers inAnti-Cancer: Liver and Brain, potential Joint Venture withWoodland Therapeutics (Dr. Nir Co-inventor and Investor)
4. ImmunoTherapy – CAR–T with Neta Madar ????

 

 

PART ONE: GDE’s Subsidiaries by Sources of Funding

Subsidiary #1 Scientific Media 

Source of Funding: via Contacts of Arie Berger and Peter Corne, Shanghai

 

Subsidiary #2 DFP (Deals, Funding & Partnerships) 

Source of Funding: via Investment Sources of Henri Cukierman in Paris

2.1 Asset Class A:  Start ups – Henri Cukierman, Paris

2.2 Asset Class B: Aviva’s  Contacts – Henri Cukierman, Paris

2.3 Asset Class C: Tech Transfer IP – Henri Cukierman, Paris

2.4 Asset Class D: M3DP Team Members: US Patent Holders

2.4.1 Bill Zurn THREE Patents for cardiovascular medical Devices – Henri Cukierman

2.4.2 Dr. Pearlman – Henri Cukierman

2.4.2.1 all IP BEFORE affiliation with LPBI [Three Patents]

2.4.2.1 all your IP AFTER affiliation with LPBI [four submissions]

Subsidiary #3 M3DP (Medical 3D BioPrinting)

3.1 M3DP – Fund raising of $20 Million

Source of Funding: contacts of Dr. Choppe, Cukierman&Co, Life Sciences

 3.1.1 VARS

3.1.2 R&D Biologics, Gene editing, Gene therapy, Tissue Engineering 

Team’s IP:

3.1.2.1 Dr. Williams and Dr. Goswami: Gene Editing & Gene Therapy

3.1.2.2 All Team: Market Intelligence on Tissue Engineering by U.S. region

3.1.3 R&D Medical Devices Applications of 3D Printing 

3.1.3.1 Dr. Pearlman’s PPA BioStent

3.1.3.2 Dr. Pearlman’s Stop MI

3.1.3.3 Dr. Pearlman’s Artificial Heart

 3.2.1 Team’s forthcoming BioMEMS

3.2.    JOINT VENTURE: SBH Sciences Inc, and M3DP – Fund raising of $10 Million

Source of Funding: Dr. Choppe, Cukierman&Co, Life Sciences

Dr. Nir and Aviva&Gerard to prepare BUSINESS PLAN AND SUBMIT TO Dr. Choppe

Project #1: Drug/Device for DM1 and DM2 by the Joint Venture

Project #2: Diagnostics Kit for Skin Cancer by Dr. Codrington

Subsidiary #4: U.S. Patents: Value Pricing and Outright Sales of IP Assets

Source of Funding: on Retainer basis – Dr. Choppe, Cukierman&Co

Mr. Bill Zurn – ALL PATENTS ISSUED  minus three MEDICAL Patents Under Subsidiary #2

Dr. Pearlman: BEFORE meeting Aviva  – Henri Cukierman – [Inventor’s Decision is Pending]

 

PART TWO: Management & Organization

 

1. develop GDE in Boston, 
2. synchronize with the Lausanne HQS
3. recruitment: 

• GDE C-Level for Subsidiary #1, #2, #3, #4
• LPBI – IT person, we are advertising at SLOAN Business School: Grebsman’s Tip
• Global BDs

5. Manage

5.1 Subsidiary #4 with Dr. Choppe

vs

5.2 Subsidiary #4 with Henri

5.3 Peter Cornes Shanghai two FUNDS

6. Bill Zurn Patents

6.1 Non-Medical Patents as Subsidiary #4 with Dr. Choppe

6.2 Medical Patents as  Subsidiary #2 with Henri

7. Manage Hlozek’s UNDER ASSAULT – Mitral Valve REPAIRTools Segment in Cardiovascular Medical Devices marketplace
8. Find a Buyer for Katie’s New Medicine Inc. Global DB Oncology Drugs and Global Oncology Trials –

Contact Google Life Sciences

9. Find Investors for Woodland Pharmaceuticals, first invest, second sell to German 3rd largest Big Pharma IB an anti Liver Fibrosis drug
10. Find Investors for profitable SBH Sciences, Inc. Dr. Raphael Nir: CEO, Chief Scientific Officer
11. Find Investors for JOINT VENTURE (SBH & M3DP)
12. Find Investors for M3DP